[{"id":"a18cecb1-f577-47bc-bd7c-470ec1fe494d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00902044","created_at":"2021-01-18T03:28:34.734Z","updated_at":"2024-07-02T16:35:23.626Z","phase":"Phase 1","brief_title":"Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma","source_id_and_acronym":"NCT00902044","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AU-101 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/11/2010","start_date":" 02/11/2010","primary_txt":" Primary completion: 12/06/2019","primary_completion_date":" 12/06/2019","study_txt":" Completion: 07/01/2032","study_completion_date":" 07/01/2032","last_update_posted":"2024-01-12"},{"id":"7b84f5ce-770d-4a13-9bc4-e1caa779cb8d","acronym":"iCAR","url":"https://clinicaltrials.gov/study/NCT02442297","created_at":"2021-01-18T11:42:04.422Z","updated_at":"2024-07-02T16:35:40.191Z","phase":"Phase 1","brief_title":"T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors","source_id_and_acronym":"NCT02442297 - iCAR","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AU-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/01/2037","study_completion_date":" 04/01/2037","last_update_posted":"2023-08-14"}]